HIGHLIGHTS
- who: Evelyn P. Murphy from the Institute, Ireland STipe Therapeutics, Denmark Universidade de Lisboa, Portugal have published the article: NR4A1-3 nuclear receptor activity and immune cell dysregulation in rheumatic diseases, in the Journal: (JOURNAL)
- what: The authors examine reports that reveal the potential of moderating NR4A 1-3 receptors as therapeutic targets in distinct models of rheumatic disease.
SUMMARY
The dysfunction of regulatory T_cells (CD4+ Fox3P+ Tregs) precedes the loss of selftolerance and the progression of disease. Both IL-23 and PGE2 stimulate interleukin-17A production by Th17 cells (comprising . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.